ArticleJournal of ovarian research2025
Long non-coding RNA HCP5 accelerated malignant progression of ovarian cancer by inhibiting ferroptosis through interaction with polypyrimidine tract binding protein 1.
Article in Journal of ovarian research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Ferroptosis-related lncRNA signature predicts prognosis and treatment response in colon cancer.Translational cancer research · 2026Article
- Advances in ferroptosis research in ovarian cancer: molecular mechanisms and therapeutic perspectives.American journal of cancer research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundOvarian cancer (OVCA) is the third most common gynaecological malignancy worldwide. Long non-coding RNA (LncRNA) HCP5 and polypyrimidine tract binding protein 1 (PTBP1) involved in regulating tumors, however, with undefined mechanism in OVCA.
methodsAfter validating lentiviral transfection efficiency, OVCA mouse models were constructed by intraperitoneal injection of ID8-Luc cells for 8 weeks, with sh-lncRNA HCP5, oe-PTBP1, and ferroptosis agonist Erastin treatment. In vivo imaging, tumor metastasis, immunohistochemistry, HE, and TUNEL staining were performed. Human ovarian adenocarcinoma cell SKOV3 cells underwent the same grouping. Interaction between lncRNA HCP5 and PTBP1 was examined using RNA immunoprecipitation and RNA pull-down assay. CCK8, flow cytometry, transmission electron microscopy, biochemical kits, qRT-PCR, and Western blot were performed.
resultsIn OVCA mice, sh-lncRNA HCP5 inhibited tumor growth and increased tumor tissue pathological damage and apoptosis, with lower PTBP1, Ki67, and B-cell lymphoma-2 (Bcl-2) expression, and higher Bcl-2 associated X and caspase-3 expression. Meanwhile, sh-lncRNA HCP5 induced ferroptosis, with reduced glutathione peroxidase 4, glutathione, and recombinant solute carrier family 7, member 11 expression, and elevated malondialdehyde, lipid peroxides, 4-hydroxynonenoic acid, acyl-CoA synthetase long chain family member 4, and transferrin receptor protein expression. These effects were reversed by oe-PTBP1, and Erastin weakened the pro-tumor role of oe-PTBP1, which were also observed in SKOV3 cells. Additionally, in vitro, lncRNA HCP5 was confirmed to bind to PTBP1, and sh-lncRNA HCP5 reduced cell viability and enhanced reactive oxygen species.
conclusionLncRNA HCP5 may promote OVCA progression by inhibiting ferroptosis through interaction with PTBP1, providing new targets in OVCA treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.